Novartis and Amgen team up to take on Alzheimer's, migraines

Strikingly, the team will focus on an oral option for Alzheimer's as it tackles CNS disorders.

By Nicole Gray • Sept. 2, 2015

Baxalta may have a new M&A-based strategy for spurning Shire

The Baxter spinoff may be on the hunt for a buyout of its own. 

By Nicole Gray • Sept. 1, 2015

Bristol-Myers sets sights on a Jakafi competitor with $1.25B fibrosis firm deal

There is only one approved drug for the treatment of myelofibrosis. BMS wants to change that.

By Nicole Gray • Sept. 1, 2015

Novo Nordisk acquiring 2 US biotechs, Calibrium and MB2

Acquisition of these two biotechs is part of Novo's larger strategy to expand its pipeline of diabetes-related drugs and foray further into the U.S. 

By Nicole Gray • Aug. 31, 2015

Why BioMarin hawked a phase III cancer drug to Medivation for $570M

Talazoparib (BMN673) is a PARP inhibitor intended to treat advanced breast cancer with BRCA1 and BRCA 2 mutations. 

By Nicole Gray • Aug. 25, 2015

Novartis snaps up MS indication for Glaxo's Arzerra

Arzerra (ofatumumab) is being studied for use in various diseases, including cancer and multiple sclerosis (MS).

By Nicole Gray • Aug. 24, 2015

Biosim behemoth? Partners Samsung and Biogen will float a $1 billion IPO

Samsung Bioepis is already working on biosimilar versions of at least five major drugs.

By Nicole Gray • Aug. 21, 2015

Valeant strikes $1B deal to snag women's libido drug maker Sprout

That was fast.

By Sy Mukherjee • Aug. 20, 2015

Genmab receives $2 million from Novo Nordisk for DuoBody platform

The DuoBody platform developed by Genmab is used to create and develop bi-specific antibody candidates.

By Nicole Gray • Aug. 17, 2015

In Mylan-Perrigo hostile takeover drama, it's proxy firm vs. proxy firm

Both companies claimed victories last week when it came to recommendations from hedge funds and third-party advisers. And this saga could soon be coming to an end. 

By Nicole Gray • Aug. 17, 2015

Roche snaps up diagnostics firm for $425M as part of antibiotics refocus

The deal for GeneWeave Biosciences includes a $190 million upfront payment. 

By Sy Mukherjee • Aug. 14, 2015

Baxalta CEO scoffs at Shire's takeover bid

He says it is based on a "lowball valuation."

By Randy Lilleston • Aug. 12, 2015

UK's Mallinckrodt to buy US immunotherapy firm Therakos for $1.33B

The deal will give Mallinckrodt a bigger footprint in pain management and expand its specialty arm. 

By Sy Mukherjee • Aug. 11, 2015

AZ, Heptares heading into immuno-oncology partnership

The deal could be worth more than $500 million. 

By Nicole Gray • Aug. 7, 2015

Shire's pursuit of Baxalta stymied by strong takeover defenses

Shire's $30 billion all-stock offer for the Baxter spinoff may not be enough to bring a deal to fruition.

By Nicole Gray • Aug. 6, 2015

India cancels EU trade talk meeting over widespread drug ban

Free trade talks between the E.U. and India may be in jeopardy as the country expresses 'disappointment' over an E.U. ban on more than 700 pharma products.

By Nicole Gray • Aug. 6, 2015

Pfizer gains EU antitrust approval for Hospira acqusition

Pfizer will be able to elbow its way into the biosimilars market with the deal. 

By Nicole Gray • Aug. 5, 2015

Shire buying Foresight Biotherapeutics and its pink eye drug for $300M

Shire's growth by acquisition strategy rolls on. 

By Nicole Gray • Aug. 4, 2015

AZ & Isis Pharma expanding collaborative gene therapy R&D

The companies are focusing on developing cardiovascualr, metabolic, and renal therapies using Isis' antisense technology plaform.

By Nicole Gray • Aug. 4, 2015

Shire offers $30B for Baxalta with sights on becoming rare disease titan

The recently-formed Baxter spinoff has declined to engage with Shire thus far. But the latter firm insists a combined company would be "the global leader in rare diseases."

By Sy Mukherjee • Aug. 4, 2015

Biologic patent life emerges as sticking point in failed TPP talks

In the latest rounds of Trans-Pacific Partnership (TPP) talks in Maui, the 12 participating countries could not finalize an agreement, and pharmaceutical patents continued to be an area of contention. 

By Nicole Gray • Aug. 2, 2015

The Teva-Allergan deal and the power of the 'focus factor'

We spoke with DRG partner John Jaeger about what’s driving deals, including the recent Teva-Allergan agreement, in what he calls the "new era of U.S. healthcare."

By Nicole Gray • July 30, 2015

Welcome to the club: Regeneron, Sanofi to team up, join cancer immunotherapy fray

It's the hottest therapeutic space in oncology, and two huge players are getting into the game.

By Nicole Gray • July 29, 2015

Allergan buys Naurex for $560 million, nabs 2 antidepressants

The drugs gained in the deal are both intravenous NMDA receptor modulators.

By Nicole Gray • July 27, 2015

Teva to snap up Allergan's generics unit for $40.5B, become Big Pharma behemoth

The deal will put an end to the company's dogged pursuit of Mylan, catapult Teva into Big Pharma's upper echelons—and is bound to raise antitrust concerns.

By Nicole Gray • July 27, 2015